SCHEMBL30765522

SCHEMBL30765522

CCCCOC(=O)NCc1[nH]c2ccncc2c1F

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HRH4 Q9H3N8 3/20 0.37
▸ HRH3 Q9Y5N1 3/20 0.37
▸ HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558589 0.81 NAMPT (0.43) L3MBTL1KDM4ECYP1A2CYP3A4HTR6
SCHEMBL30097047 0.70 FAAH (0.44) FAAHL3MBTL1ALDH1A1CYP1A2MAPT
SCHEMBL13097907 0.68 CYP2D6 (0.52) ALDH1A1KDM4EHPGDTSHRSMN1; SMN2
SCHEMBL31558539 0.68 NAMPT (0.43) L3MBTL1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL30765895 0.68 NAMPT (0.43) L3MBTL1KDM4ECYP1A2CYP3A4MAPT
SCHEMBL6647297 0.67 TRPV1 (0.54) FAAHKDM4ECYP1A2MAPTTSHR
SCHEMBL13387445 0.67 FAAH (0.58) FAAHTSHRSMN1; SMN2
SCHEMBL17794456 0.64 ACHE (0.53) L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5962440 0.64 LMNA (0.55) FAAHL3MBTL1ALDH1A1CYP1A2CYP3A4
SCHEMBL8507123 0.64 HPGD (0.67) L3MBTL1ALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 — — EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback